Your session is about to expire
← Back to Search
Testosterone + Enzalutamide for Prostate Cancer
Study Summary
This trial will analyze the effects of oral testosterone therapy given on a schedule of seven days of therapy followed by seven days of no therapy for a 28 day cycle in men with metastatic castrate resistant prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is getting worse despite hormone therapy.I have received docetaxel treatment for prostate cancer.I do not have an active, uncontrolled infection like HIV/AIDS or chronic hepatitis.My cancer has spread and can be measured on a CT scan.I can understand and am willing to sign the consent form.I am a man aged 18 or older.I need a catheter to urinate because of a blockage.I can take care of myself but might not be able to do heavy physical work.I agree to continue hormone therapy during the trial.I had a blood clot in the last 2 years and am not on blood thinners.I don't have severe sleep apnea, uncontrolled heart issues, or a high hematocrit level.I need painkillers for my prostate cancer pain.My condition could worsen with testosterone therapy.I am currently taking Coumadin.My prostate cancer diagnosis was confirmed through a tissue examination.My prostate cancer is getting worse despite hormone therapy.I have received treatment for advanced prostate cancer that did not respond to hormonal therapy.I am currently on prednisone and cannot stop taking it.I had surgery, recovered for 4 weeks, and have no major side effects.
- Group 1: Oral Testosterone Therapy given until radiographic progression followed by Enzalutamide Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment available for this experiment at the moment?
"According to clinicaltrials.gov, this medical trial is presently accepting participants. It was initially posted on March 7th 2022 and the details were most recently modified on May 6th of the same year."
In what type of medical conditions is Testosterone Undecanoate commonly prescribed?
"Testosterone Undecanoate is a viable therapeutic option for treating hypogonadotropic hypogonadism, castration-associated syndromes, and hypergonadotropic hypogonadism."
What potential risk factors are associated with Testosterone Undecanoate?
"Testosterone Undecanoate has had prior safety data collected, granting it a score of 2. Thus far, there have been no studies which demonstrate efficacy in this field."
Are there any previous investigations involving Testosterone Undecanoate?
"Presently, 105 clinical trials researching Testosterone Undecanoate are being conducted, 30 of which are in the third phase. While Germantown, Tennessee is home to many of these investigations, 5783 sites across the world have studies for this medication running too."
How many participants are engaged in this clinical trial?
"Indeed, the research hosted on clinicaltrials.gov indicates that this medical trial started recruiting participants on March 7th 2022 and is still actively doing so. The team needs to enroll thirty individuals across one site."
Share this study with friends
Copy Link
Messenger